Couples' Reasons for Adherence to, or Discontinuation of, PDE Type 5 Inhibitors for Men with Erectile Dysfunction at 12 to 24-Month Follow-Up after a 6-Month Free Trial

Journal of Sexual Medicine

Volumn 9, Issue 3, 2012, Pages 857-865

  Conaglen, Helen M ^a   Conaglen, John V ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Adherence; Couples; Discontinuation; Erectile Dysfunction; Phosphodiesterase Type 5 Inhibitors; Sildenafil; Tadalafil; Vardenafil

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL;

ADULT; ALCOHOL ABUSE; ARTICLE; DRUG PREFERENCE; DRUG TREATMENT FAILURE; ERECTILE DYSFUNCTION; FEAR; FEMALE; FOLLOW UP; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; INTERPERSONAL COMMUNICATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT DECISION MAKING; PRIORITY JOURNAL; SEXUALITY;

EID: 84857643548     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2011.02625.x     Document Type: Article

References (36)

1. Althof SE. When an erection alone is not enough: Biopsychosocial obstacles to lovemaking. Int J Impot Res 2002;14(suppl 1):S99-S104.
2. Althof SE, Leiblum SR, Chevret-Measson M, Hartmann U, Levine SB, McCabe MP, Plaut M, Rodrigues O, Wylie K. Psychological and interpersonal dimensions of sexual function and dysfunction. J Sex Med 2005;2:793-800.
3. Althof SE, Turner LA, Levine SB, Bodner D, Kursh ED, Resnick MI. Through the eyes of women: The sexual and psychological responses of women to their partner's treatment with self-injection or external vacuum therapy. J Urol 1992;147:1024-7.
4. Althof SE, Turner LA, Levine SB, Risen C, Bodner D, Kursh ED, Resnick MI. Sexual, psychological, and marital impact of self injection of papaverine and phentolamine: A long term prospective study. J Sex Marital Ther 1991;17:101-12.
5. Althof SE, Turner LA, Levine SB, Risen C, Kursh E, Bodner D, Resnick M. Why do so many people drop out from auto-injection therapy for impotence? J Sex Marital Ther 1989;15:121-9.
6. Althof SE, Turner LA, Levine SB, Risen C, Kursh ED, Bodner D, Resnick M. Intracavernosal injection in the treatment of impotence: A prospective study of sexual, psychological, and marital functioning. J Sex Marital Ther 1987;13:155-65.
7. Althof SE, Eid JF, Talley DR, Brock GB, Dunn ME, Tomlin ME, Natanegara F, Ahuja S. Through the eyes of women: The partners' perspective on tadalafil. Urology 2006;68:631-5.
8. Candru P, Sundaram WT, Pryor LE, Sidi AA, Billups K, Pryor JL. Long term follow up of patients receiving injection therapy for erectile dysfunction. Urology 1997;49:932-5.
9. Gupta R, Kirschen J, Barrow RC, Francios J. Predictors of success and risk factors for attrition in the use of intracavernous injection. J Urol 1997;157:1681-6.
10. Kramarsky-Binkhorst S. Female partner perception of Small-Carrion implant. Urology 1978;12:545-8.
11. Bettocchi C, Palumbo F, Spilotros M, Lucarelli G, Ricapito VD, Palazzo S, Battaglia M, Selvaggi FP, Ditonno P. penile prosthesis implant: When, what and how. JMH 2009;6:299-306.
12. Al-Shaiji TF, Brock GB. Phosphodiesterase type 5 inhibitors for the management of erectile dysfunction: Preference and adherence to treatment. Curr Pharm Des 2009;15:3486-95.
13. El-Galley R, Rutland H, Talic R, Keane T, Clark H. Long-term efficacy of sildenafil and tachyphylaxis effect. J Urol 2001;166:927-31.
14. Giannitsas K, Konstantinopoulos A, Patsialas C, Perimenis P. Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction. Patient Prefer Adherence 2008;2:149-55.
15. Hatzichristou D, Haro JM, Martin-Morales A, von Keitz AV, Riley A, Bertsch J, Belger M, Wolka AM, Beardsworth A; EDOS Group. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: Results from the Erectile Dysfunction Observational Study. Int J Clin Pract 2007;61:1850-62.
16. Jiann B-P, Yu C-C, Su C-C, Tsai J-Y. Compliance of sildenafil treatment for erectile dysfunction and factors affecting it. Int J Impot Res 2006;18:146-9.
17. Jiann B-P, Yu C-C, Tsai J-Y, Wu TT, Lee Y-H, Huang J-K. What to learn about sildenafil in the treatment of erectile dysfunction from 3-year clinical experience. Int J Impot Res 2003;15:412-7.
18. Klotz T, Mathers M, Klotz R, Sommer F. Why do patients with erectile dysfunction abandon effective therapy with sildenafil (Viagra)? Int J Impot Res 2005;17:2-4.
19. Ljunggren C, Hedelin H, Salomonsson K, Ströberg P. Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance. J Sex Med 2008;5:469-75.
20. Mulhall JP, McLaughlin TP, Harnett JP, Scott B, Burhani S, Russell D. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction. J Sex Med 2005;2:848-55.
21. Padma-Nathan H, Eardley I, Kloner RA, Laties AM, Montorsi F. A 4-year update on the safety of sildenafil citrate (Viagra). Urology 2002;60:67-90.
22. Sato Y, Tanda H, Kato S, Onishi S, Nitta T, Koroku M. How long do patients with erectile dysfunction continue to use sildenafil citrate? Dropout rate from treatment course as outcome in real life. Int J Urol 2007;14:339-42.
23. Son H, Park K, Kim S-W, Paick J-S. Reasons for discontinuation of sildenafil citrate after successful restoration of erectile function. Asian J Androl 2004;6:117-20.
24. Souverein PC, Egberts ACG, Meuleman EJH, Urquhart J, Leufkens HGM. Incidence and determinants of sildenafil (dis)continuation: The Dutch cohort of sildenafil users. Int J Impot Res 2002;14:259-65.
25. Ströberg P, Hedelin H, Bergström A. Is sex only for the healthy and wealthy? J Sex Med 2007;4:176-82.
26. Giuliano FO, Montorsi F, Mirone V, Rossi D, Sweeney M. Switching from intracavernous prostaglandin e1 injections to oral sildenafil citrate in patients with erectile dysfunction: Results of a multicenter European study. J Urol 2000;164:708-11.
27. Cayan S, Bozlu M, Canpolat B, Akbay E. The assessment of sexual functions in women with male partners complaining of erectile dysfunction: Does treatment of male sexual dysfunction improve partner's sexual functions? J Sex Marital Ther 2004;30:333-41.
28. Chevret M, Jaudinot E, Sullivan K, Marrel A, Solesse de Gendre A. Impact of erectile dysfunction (ED) on sexual life of female partners: Assessment with the index of sexual life (ISL) questionnaire. J Sex Marital Ther 2004;30:157-72.
29. Conaglen HM, Conaglen JV. The impact of erectile dysfunction on female partners: A qualitative investigation. Sex Relat Ther 2008;23:147-56.
30. Conaglen HM, Conaglen JV. Investigating women's preference for sildenafil or tadalafil use by their partners with erectile dysfunction: The partners' preference study. J Sex Med 2008;5:1198-207.
31. McCabe MP, O'Connor EJ, Conaglen HM, Conaglen JV. The impact of oral ED medication on female partners' relationship satisfaction. J Sex Med 2010;8:479-83.
32. Eardley I, Fisher A, McCabe MP, Sand MTI. Associations between female partner attitudes and male-partner erectile dysfunction, treatment-seeking behaviour and treatment utilisation: Findings of the FEMALES study. J Sex Med 2008;5:55.
33. Fisher WA, Rosen RC, Eardley I, Sand M, Goldstein I. Sexual experience of female partners of men with erectile dysfunction: The female experience of men's attitudes to life events and sexuality (FEMALES) study. J Sex Med 2008;5(supp2):55-6.
34. Fisher WA, Rosen RC, Mollen M, Brock GB, Karlin G, Pommerville P, Goldstein I, Bangerter K, Bandel TJ, Derogatis LR, Sand M. Improving the sexual quality of life of couples affected by erectile dysfunction: A double-blind, randomized, placebo-controlled trial of vardenafil. J Sex Med 2005;2:699-708.
35. Hackett G, Kell P, Ralph D, Dean J, Price D, Speakman M, Wylie K; British Society for Sexual Medicine. British Society for Sexual Medicine guidelines on the management of erectile dysfunction. J Sex Med 2008;5:1841-65.
36. Jarow JP, Burnett AL, Geringer AM. Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J Urol 1999;162:722-5.